Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.
Altimmune management will host a conference call at 8:30 am E.T. on November 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to twelve months.
About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Investor and Media Contact:
Richard EisenstadtChief Financial OfficerPhone: 240-654-1450[email protected]
Source: Altimmune, IncSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ryder System (R) Tops Q1 EPS by 43c
- Man Group PLC : Form 8.3 - Tyman plc
- Man Group PLC : Form 8.3 - Tritax Big Box REIT plc
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!